OTCMKTS:INVVY Indivior (INVVY) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free INVVY Stock Alerts $21.85 -0.40 (-1.82%) (As of 06/9/2023) Add Compare Share Share Today's Range$21.64▼$21.8550-Day Range$21.85▼$21.8552-Week Range$14.76▼$35.50Volume8,100 shsAverage Volume3,825 shsMarket Capitalization$3.01 billionP/E Ratio20.81Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Indivior alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Indivior Stock (OTCMKTS:INVVY)Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Read More INVVY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVVY Stock News HeadlinesApril 21, 2024 | ft.comPsychology class: Indivior aims to move primary listing from London to New YorkMarch 6, 2024 | finance.yahoo.comZacks.com featured highlights Modine Manufacturing, Indivior and InterfaceApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 22, 2024 | marketwatch.comIndivior Shares Jump on Possible U.S. Listing, Swing to Pretax ProfitFebruary 22, 2024 | msn.comIndivior shares soar as pharma firm ponders primary listing in the USFebruary 22, 2024 | msn.comDrug maker Indivior considers ditching primary UK listing for USFebruary 22, 2024 | uk.finance.yahoo.comUPDATE 1-UK-listed Indivior plans shifting to US bourses by summerFebruary 22, 2024 | ca.news.yahoo.comDrugmaker Indivior consults on moving primary listing from London to USApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 22, 2024 | finance.yahoo.comIndivior plans shifting primary listing to U.S.February 22, 2024 | ft.comIndivior aims to move primary listing from London to New YorkFebruary 22, 2024 | msn.comIndivior plans primary US listing in another hit to London’s flagging equity marketJanuary 16, 2024 | thetimes.co.ukIndivior boss brings promise of a pick-me-up for staffDecember 20, 2023 | marketwatch.comIndivior Resolves Patent Disputes With ActavisDecember 5, 2023 | lse.co.ukIndivior and Reckitt land legal boost in UK Suboxone claimDecember 5, 2023 | marketwatch.comIndivior Says UK High Court Strikes Claims Against It and Reckitt BenckiserNovember 17, 2023 | lse.co.ukIndivior to keep Scopia's Jerome Lande on board as agreement extendedNovember 17, 2023 | marketwatch.comIndivior Extends Relationship, Board Representation of Major ShareholderNovember 17, 2023 | lse.co.ukUPDATE: Indivior plans up to USD100 million share buyback programmeNovember 17, 2023 | marketwatch.comIndivior to Begin $100 Mln Share BuybackNovember 9, 2023 | uk.finance.yahoo.comIndivior Announces Q3 2023 Financial ResultsNovember 9, 2023 | lse.co.ukIndivior swings to quarterly loss on costs despite strong salesNovember 9, 2023 | marketwatch.comIndivior Swings to Pretax Loss on Higher Costs; Backs Revenue ViewOctober 24, 2023 | reuters.comIndivior to pay $385 mln to settle Suboxone claims by direct purchasersOctober 23, 2023 | thetimes.co.ukIndivior freed up to fight global crisisOctober 23, 2023 | reuters.comUPDATE 1-Indivior to pay $385 mln to end Suboxone monopoly lawsuitsOctober 23, 2023 | msn.comIndivior to pay $385 million to end final Suboxone monopoly lawsuitsSee More Headlines Receive INVVY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:INVVY Previous SymbolNASDAQ:INVVY CUSIPN/A CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees800Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio20.81 Forward P/E Ratio17.62 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$791 million Price / Sales3.81 Cash Flow$1.15 per share Price / Cash Flow18.94 Book Value$1.45 per share Price / Book15.07Miscellaneous Outstanding Shares137,880,000Free FloatN/AMarket Cap$3.01 billion OptionableNot Optionable Beta0.35 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMark CrossleyChief Executive Officer & Executive DirectorRyan PreblickChief Financial Officer & Executive DirectorChristian HeidbrederChief Scientific OfficerCynthia CetaniChief Compliance & Integrity OfficerNina DeLorenzoChief Global Impact OfficerKey CompetitorsIDEAYA BiosciencesNASDAQ:IDYAArrowhead PharmaceuticalsNASDAQ:ARWRHUTCHMEDNASDAQ:HCMAmicus TherapeuticsNASDAQ:FOLDXenon PharmaceuticalsNASDAQ:XENEView All Competitors INVVY Stock Analysis - Frequently Asked Questions How have INVVY shares performed in 2024? Indivior's stock was trading at $21.8455 at the start of the year. Since then, INVVY shares have increased by 0.0% and is now trading at $21.8455. View the best growth stocks for 2024 here. How do I buy shares of Indivior? Shares of INVVY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:INVVY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
